血液恶性肿瘤及造血干细胞移植患者乙型肝炎病毒再激活的筛查、监测、预防、预防性治疗及治疗建议
该立场文件由意大利多个科学学会专家会议及系统文献综述制定,采用GRADE方法评估推荐质量,针对血液恶性肿瘤和/或造血干细胞移植患者HBV再激活的筛查、监测、预防、治疗和疫苗接种提出推荐。推荐包括化疗前筛查HBsAg、anti-HBc和HBV DNA,未预防者每月监测HBV DNA,HBsAg阳性及HSCT患者使用第三代抗病毒药预防,anti-HBc阳性淋巴瘤及HSCT患者接受预防,所有HBV阴性患者接种疫苗。
要点
- 化疗前应筛查HBsAg、anti-HBc和HBV DNA。
- 未预防的HBV阳性患者应每月监测HBV DNA。
- HBsAg阳性及HSCT患者应使用第三代抗病毒药预防。
核心结论
- 血液恶性肿瘤和/或HSCT患者应进行HBV筛查,HBsAg阳性及anti-HBc阳性特定患者应接受抗病毒预防,HBV阴性患者应接种疫苗。
关键数值与推荐
- 化疗前应筛查HBsAg、anti-HBc和HBV DNA。
- 所有未接受预防的HBV阳性患者应每月监测HBV DNA。
- HBsAg阳性血液病患者及HSCT患者应接受第三代抗病毒治疗作为预防。
- anti-HBc阳性淋巴瘤患者及HSCT患者应接受抗病毒预防。
- 所有HBV阴性血液病患者应接种HBV疫苗。
临床怎么用
- 对血液恶性肿瘤和HSCT患者,化疗前筛查HBsAg、anti-HBc和HBV DNA,未预防者每月监测HBV DNA,HBsAg阳性及HSCT患者使用第三代抗病毒药预防,anti-HBc阳性淋巴瘤及HSCT患者接受预防,HBV阴性者接种疫苗。
局限性
- 原文指出该领域信息有限,希望未来获得设计良好的研究数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SCOPE: Hepatitis B virus (HBV) infection reactivation is associated with high morbidity and mortality in patients with haematologic malignancy and/or haematopoietic stem cell transplantation (HSCT). However, information on this issue is limited. The scope of this position paper is to provide recommendations on HBV screening, monitoring, prophylaxis, treatment and vaccination in the patients described above. METHODS: These recommendations were developed from one meeting of experts attended by different Italian scientific societies as well as from a systematic literature review (of articles published through December 31, 2016) on HBV infection in haematologic patients and in patients who underwent haematopoietic stem cell transplantation published in the same issue of the journal. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess each recommendation's quality. QUESTIONS ADDRESSED: These recommendations provide the answers to the following questions: (a) HBV screening and monitoring: Who should be screened before chemotherapy? Which screening tests should be used? Should HBV-DNA detection be used to monitor HBV reactivation before starting antivirals? What is the best timeline to monitor HBV reactivation? (b) Prophylaxis in HBsAg-positive patients: Which antiviral drugs should be used to treat HBsAg-positive patients? How long should antiviral prophylaxis be provided to HBsAg-positive patients? (c) Prophylaxis in patients with resolved HBV infection: Which patients with resolved HBV infection should receive antiviral prophylaxis? Which antiviral drug should be used? How long should antiviral prophylaxis be provided? (d) HBV infection management strategy in autologous (auto-HSCT) and allogeneic HSCT (allo-HSCT): Which HSCT recipients should receive antiviral prophylaxis? Which antiviral drug should be used? How long should antiviral prophylaxis be provided? (e) Choice of antiviral drugs in the treatment of HBV reactivation: Should third-generation anti-HBV drugs be preferred to first- or second-generation antiviral drugs in the treatment of HBV reactivation with or without hepatitis flare in haematologic patients? (f) Immunization against HBV in patients with haematologic malignancies and/or patients who underwent HSCT: Should these patients be vaccinated? Which HBV vaccination schedule should be adopted? RECOMMENDATIONS: Haematologic patients should be screened for hepatitis B surface antigen (HBsAg) plus anti-hepatitis B core protein (HBc), and HBV DNA before chemotherapy. HBV DNA levels should be monitored monthly in all HBV-positive patients who do not receive prophylaxis. HBsAg-positive haematologic patients and those undergoing HSCT should receive third-generation antiviral therapy as prophylaxis. Anti-HBc-positive lymphoma patients and those receiving HSCT should receive antiviral prophylaxis. All HBV-negative haematologic patients should be vaccinated for HBV. The acquisition of data from well-designed studies is desirable in the near future.
引用
- Sarmati L, Andreoni M, Antonelli G, et al. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper. Clin Microbiol Infect. 2017. PMID: 28668466. doi:10.1016/j.cmi.2017.06.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。